Send the following on WhatsApp
Continue to Chathttps://de.marketscreener.com/kurs/aktie/SEAGEN-INC-10808/news/Genmab-und-Seagen-Tivdak-Studie-zu-Gebarmutterhalskrebs-erreicht-Endpunkt-des-Gesamtuberlebens-44766760/?utm_source=whatsapp&utm_medium=social&utm_campaign=share